• GuptaAnupam DattaAD0000-0001-5182-6919Central Adelaide Local Health Network, Queen Elizabeth Hospital (SA), University of Adelaide, Adelaide, South Australia, Australia., Ian Baguley, John Estell, Saul Geffon, Kong Goh, Barry Rawicki, Stephen de Graaf, and John Olver.
• Central Adelaide Local Health Network, Queen Elizabeth Hospital (SA), University of Adelaide, Adelaide, South Australia, Australia.
• Intern Med J. 2024 Jan 1; 54 (1): 178182178-182.

AbstractThe Rehabilitation Medicine Society of Australia and New Zealand advocates the safe, effective and evidence-based use of botulinum toxin type A for spasticity management. The process requires appropriate training, alongside considerable knowledge and skills, to maximise efficacy. The processes before and after injection contribute to effectiveness. The gold standard of managing spasticity is for assessment by a multidisciplinary specialist team, deriving patient-centric goals, and designing an injection protocol to match these goals. The patient and/or carers are considered part of the decision-making team. Postinjection therapy and measurement of goal achievement are highly recommended as part of the wider holistic approach to management. The Society believes treatment failures can be minimised by following clear clinical guidelines.© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.

9 keywords...

hide…